Kikuchi K
Gan To Kagaku Ryoho. 1983 Feb;10(2 Pt 2):551-8.
Many hybridoma monoclonal antibodies to lymphocytes of T cell and B cell lineage and of both T and B cell lineage and stem cells were newly developed and characterized. Lymphocyte surface antigens that appear at the specific stages of T and B cell differentiation were clearly detected by these monoclonal antibodies. These antigens were also expressed on the cell surface of lymphatic leukemias and malignant lymphomas, suggesting the differentiation stages from which the tumor was derived. Leukemias and malignant lymphomas were diagnosed and classified objectively with these monoclonal antibodies. Immunohistochemical approach with the antibodies was very helpful for diagnosis of malignant lymphomas. Since the cell surface phenotypes are often related to biological behavior of the cell, the classification was expected to reflect the pathologic expression of tumor cells, and to have relationship with the clinical course of the patients with lymphoid malignancies. In fact, it has been suggested that the classification of leukemia and lymphoma based on the antigens defined by the monoclonal antibodies is related to the clinical features and prognosis of the patients.
许多针对T细胞系、B细胞系以及T和B细胞系及干细胞的淋巴细胞的杂交瘤单克隆抗体被新开发并进行了表征。通过这些单克隆抗体能够清晰地检测到在T细胞和B细胞分化的特定阶段出现的淋巴细胞表面抗原。这些抗原也在淋巴白血病和恶性淋巴瘤的细胞表面表达，提示了肿瘤所源自的分化阶段。利用这些单克隆抗体对白血病和恶性淋巴瘤进行了客观的诊断和分类。使用这些抗体的免疫组织化学方法对恶性淋巴瘤的诊断非常有帮助。由于细胞表面表型通常与细胞的生物学行为相关，因此预期这种分类能够反映肿瘤细胞的病理表现，并与淋巴系统恶性肿瘤患者的临床病程相关。事实上，已经有人提出基于单克隆抗体所定义的抗原对白血病和淋巴瘤进行的分类与患者的临床特征和预后相关。
